COMMUNIQUÉS West-GlobeNewswire

kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics
09/03/2026
Innovative glycobiology platform aimed at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas PARIS, March 09, 2026 (GLOBE NEWSWIRE) -- kyron.bio , a [...]
Claritas Neuroclould™ Receives Approval from Brazil Regulator ANVISA to Market the Software Device for Brain Imaging Analysis, Localisation and Quantification in PET, SPECT and MRI
09/03/2026
LONDON and SAO PAULO, March 09, 2026 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image enhancement, noise reduction, segmentation and [...]
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
09/03/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK ® ( [...]
Novo Nordisk A/S - share repurchase programme
09/03/2026
Bagsværd, Denmark, 9 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
09/03/2026
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbociclib was well [...]
TME PHARMA PROLONGE SA CAPACITÉ FINANCIÈRE À PLUS DE 12 MOIS
09/03/2026
TME PHARMA PROLONGE SA CAPACITÉ FINANCIÈRE À PLUS DE 12 MOIS Berlin, Allemagne, 9 mars 2025, 8 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie au stade clinique spécialisée dans [...]
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
09/03/2026
PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik ® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is [...]
Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde
09/03/2026
PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik ® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes les indications. La [...]
Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering
09/03/2026
Oslo, Norway, 09 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a [...]
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy
09/03/2026
Comparable long-term effectiveness to classic corticosteroids, both prednisone (p=0.8587) and deflazacort (p=0.6544), based on time to loss of ambulation 80% fewer patients with vertebral fractures (8.1% vs 41.9% on [...]
TME Pharma extends financial runway to over 12 months
09/03/2026
TME Pharma extends financial runway to over 12 months Berlin, Germany , March 9, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development [...]
TimelyCare Launches TimelyPulse to Help Colleges Spot Struggling Students Before It’s Too Late
09/03/2026
New proactive engagement solution aims to close the gap between early signals and meaningful follow-through Fort Worth, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Colleges and universities have invested heavily in early [...]
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
08/03/2026
- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-rostudirsen [...]
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
08/03/2026
NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
08/03/2026
Please see enclosed pdf. Attachment 08032026_trading_in_shares_GL
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
08/03/2026
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary [...]
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
08/03/2026
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development [...]
MagnesiumFreeze Sciatic Nerve Claims Evaluated: Consumer Research Report Examines Magnesium Niacinamide Relief Topical Cream Ingredients, NAD+ Science, and Sciatic Nerve Support Discussions
07/03/2026
A 2026 informational consumer research report examining MagnesiumFreeze (Magnesium Niacinamide Relief) topical nerve support claims, ingredient research context, pricing disclosures, and verification considerations for [...]
AIM ImmunoTech Announces Closing of its Rights Offering
07/03/2026
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]

Pages